Triathlon Medical Ventures

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Tolera Therapeutics Inc. is a biotechnology company established under the leadership of Dr. Maria Siemionow, an expert in microsurgery and transplantation. Originating as a spin-off of the Cleveland Clinic, Tolera focuses on developing advanced immune modulation therapies aimed at enhancing organ and tissue transplant acceptance while minimizing the need for chronic immunosuppression. The company’s innovative approach targets the human alpha-beta T-cell receptor, which helps render pathologic T-cells inert. This unique signaling pathway promotes the expansion of regulatory T-cells in a non-depleting manner, addressing unmet medical needs for patients with a range of autoimmune and immune-mediated diseases. Through its research, Tolera Therapeutics aims to provide safer, more effective solutions that improve patient outcomes and quality of life.

Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing regenerative therapies. Founded in 2007, it focuses on treating life-threatening diseases using non-viral gene therapies that activate natural processes to repair the body.

Tolera Therapeutics Inc. is a biotechnology company established under the leadership of Dr. Maria Siemionow, an expert in microsurgery and transplantation. Originating as a spin-off of the Cleveland Clinic, Tolera focuses on developing advanced immune modulation therapies aimed at enhancing organ and tissue transplant acceptance while minimizing the need for chronic immunosuppression. The company’s innovative approach targets the human alpha-beta T-cell receptor, which helps render pathologic T-cells inert. This unique signaling pathway promotes the expansion of regulatory T-cells in a non-depleting manner, addressing unmet medical needs for patients with a range of autoimmune and immune-mediated diseases. Through its research, Tolera Therapeutics aims to provide safer, more effective solutions that improve patient outcomes and quality of life.

Juventas Therapeutics is a privately-held clinical-stage biotechnology company developing regenerative therapies. Founded in 2007, it focuses on treating life-threatening diseases using non-viral gene therapies that activate natural processes to repair the body.

Tolera Therapeutics Inc. is a biotechnology company established under the leadership of Dr. Maria Siemionow, an expert in microsurgery and transplantation. Originating as a spin-off of the Cleveland Clinic, Tolera focuses on developing advanced immune modulation therapies aimed at enhancing organ and tissue transplant acceptance while minimizing the need for chronic immunosuppression. The company’s innovative approach targets the human alpha-beta T-cell receptor, which helps render pathologic T-cells inert. This unique signaling pathway promotes the expansion of regulatory T-cells in a non-depleting manner, addressing unmet medical needs for patients with a range of autoimmune and immune-mediated diseases. Through its research, Tolera Therapeutics aims to provide safer, more effective solutions that improve patient outcomes and quality of life.